3.229.124.74
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Nephrology
Trending Topics

Review: SGLT2 Inhibitors as a Potential Treatment for Alport Syndrome

Posted on February 27, 2020

In this review, the authors discuss sodium-glucose co-transporter-2 (SGLT2) inhibitors as a potential treatment in Alport syndrome, a rare genetic disease characterized by kidney disease and ocular and auditory defects. There is no cure but therapeutic blockade of the renin-angiotensin-aldosterone system can slow the progression of end-stage kidney disease (ESKD).

Recent clinical trials in chronic kidney disease have shown good cardiovascular and renal outcomes in patients with diabetes mellitus treated with SGLT2 inhibitors. SGLT2 inhibitors have been found to have additional nephroprotective properties which make them a potential treatment option in progressive kidney disease.

Read the full abstract here.

Reference

Mabillard H and Sayer JA. SGLT2 inhibitors – a potential treatment for alport syndrome. Clin Sci (Lond). 2020;134(4):379-388. DOI: 10.1042/CS20191276

-Advertisement-
Related Articles
Optimizing Electronic Health Record Data for Diagnosing Rare Diseases
May 29, 2021
The American Society of Nephrology Offers Informational Webinar on New COVID-19 Guidance for Dialysis Facilities
Jun 02, 2020
Attendee at Kidney Conference Tests Positive for COVID-19
Jun 02, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-